Crossmark

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-61691-4

Published Online: 2025-07-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fennell, Dean A. https://orcid.org/0000-0001-7373-1312
Hill, Kayleigh https://orcid.org/0000-0001-5289-4454
Zhang, Min

Poile, Charlotte

Ewings, Sean

Baitei, Essa Y.

Dzialo, Joanna https://orcid.org/0000-0001-6083-7687
Nusrat, Nada

Rogel, Jan

Faulkner, Daniel https://orcid.org/0000-0003-3438-7330
Ottensmeier, Christian https://orcid.org/0000-0003-3619-1657
Califano, Raffaele

Hanna, Gerard G. https://orcid.org/0000-0003-1003-5138
Danson, Sarah

Steele, Nicola

Nye, Mavis

Johnson, Lucy

Mallard, Kim

Lord, Joanne

Middleton, Calley

Szlosarek, Peter

Chan, Sam

Darlison, Liz

Wells-Jordan, Peter

Richards, Cathy

Harber, James https://orcid.org/0000-0001-6451-9598
Bzura, Aleksandra

Spicer, Jake

Pritchard, Catrin

Kamata, Tamihiro

Hahne, Jens C.

Jama, Maymun

Hollox, Edward J. https://orcid.org/0000-0002-0115-2298
Lester, Jason F.

Luo, Jin-Li

Zhou, Zisen https://orcid.org/0000-0001-6122-5586
Yang, Hongji https://orcid.org/0000-0001-6561-3631
Zhou, Huiyu

Klampatsa, Astero https://orcid.org/0000-0003-0572-502X
Griffiths, Gareth O. https://orcid.org/0000-0002-9579-8021
Funding

Funding for this research was provided by:

Cancer Research UK (C16728/A21400)
License Information

Text and Data Mining valid from 2025-07-21

Version of Record valid from 2025-07-21
More Information

Article History

Received: 11 October 2024

Accepted: 27 June 2025

First Online: 21 July 2025

Competing interests

: DAF reports grants from Aldeyra, Astex Therapeutics, Bayer, Bergen Bio, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Iovance, Merck Sharp & Dohme, Owkin, RS Oncology; non-financial support from Clovis, Eli Lilly, Roche, and Bristol Myers Squibb. Personal fees from Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Orion, RS Oncology and non-financial support from Roche. GG reports grants from Jannsen-Cilag, Novartis, Astex, Roche, Heartflow, Bristol Myers Squibb, BioNtech; grants and personal fees from AstraZeneca; and personal fees from Celldex, outside the submitted work. JL reports grants from Cancer Research UK and non-financial support from Bristol Myers Squibb. CO reports personal fees from Bristol Myers Squibb. RC reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Roche, and AstraZeneca. All other authors declare no competing interests.

Document is current

Any future updates will be listed below